MolMed expands in the United States the Phase III trial of TK for the treatment of high-risk leukaemia
MolMed announces the enrolment of the first patient in the United States, initiating the cross-Atlantic expansion of the pivotal Phase III trial (TK008) of its proprietary TK cell/gene therapy for high-risk leukaemia patients. The study, already ongoing in Europe, foresees patient enrolment in 16 clinical centres worldwide. Claudio Bordignon, Chairman of the Board and CEO ...